Learn about:
- JAMES
- BET
Meet James, a patient you may see in your practice
Patient name:
James, 52
Occupation:
Middle school teacher
Patient History
- Has been seeing a primary care physician for gout for the last 15 years—his disease has rapidly progressed
- Flares: 6 in the last year
- 2 resulted in urgent care visits
- 3 mitigated with flare prophylaxis
- 1 mitigated with a cortisone injection
- Pain: complaining of pain in his feet
- Tophi: tophi on his hands, feet, specifically ankle and MTP joint, and elbows
- Comorbidities: diabetes
sUA, serum uric acid.
KRYSTEXXA is not indicated for the treatment of pain.
sUA:
9.3 mg/dL
BMI:
31
G6PD:
normal
A1C:
7.3%
Allopurinol:
300 mg QD (for the past year)
Metformin:
850 mg QD
Linagliptin:
5 mg QD
Colchicine:
0.6 mg QD for prophylaxis
Naproxen:
500 mg BID
- Uncontrolled gout has affected James’s ability to present in class and educate his students due to an increase in gout flares
- Tophi growth has caused him to feel self-conscious when students talk about his “bumpy hands”
- James has been absent from work every few months due to heightened flare pain in his feet and difficulty moving around. This has made him nervous about job security, resulting in financial worry
sUA, serum uric acid.
KRYSTEXXA is not indicated for the treatment of pain.
Learn about Bet, a real patient on KRYSTEXXA
REAL PATIENT
Patient name/age:
Bet, 43
Patient Characteristics
- sUA: >6 mg/dL
- Frequent flares: >2/year
- Tophi: Visible tophi
- Failed oral ULTs (allopurinol and febuxostat)
Best results seen at 6-12 months. Optimal treatment duration has not been established. Individual results may vary.4